Literature DB >> 17317178

Design, synthesis, and antiviral properties of 4'-substituted ribonucleosides as inhibitors of hepatitis C virus replication: the discovery of R1479.

David B Smith1, Joseph A Martin, Klaus Klumpp, Stewart J Baker, Peter A Blomgren, Rene Devos, Caroline Granycome, Julie Hang, Christopher J Hobbs, Wen-Rong Jiang, Carl Laxton, Sophie Le Pogam, Vincent Leveque, Han Ma, Graham Maile, John H Merrett, Arkadius Pichota, Keshab Sarma, Mark Smith, Steven Swallow, Julian Symons, David Vesey, Isabel Najera, Nick Cammack.   

Abstract

A series of 4'-substituted ribonucleoside derivatives has been prepared and evaluated for inhibition of hepatitis C virus (HCV) RNA replication in cell culture. The most potent and non-cytotoxic derivative was compound 28 (4'-azidocytidine, R1479) with an IC(50) of 1.28 microM in the HCV replicon system. The triphosphate of compound 28 was prepared and shown to be an inhibitor of RNA synthesis mediated by NS5B (IC(50)=320 nM), the RNA polymerase encoded by HCV. Data on related analogues have been used to generate some preliminary requirements for activity within this series of nucleosides.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17317178     DOI: 10.1016/j.bmcl.2007.02.004

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  23 in total

1.  Anti-hepatitis C virus activity of novel beta-d-2'-C-methyl-4'-azido pyrimidine nucleoside phosphoramidate prodrugs.

Authors:  Ramu Rondla; Steven J Coats; Tamara R McBrayer; Jason Grier; Melissa Johns; Phillip M Tharnish; Tony Whitaker; Longhu Zhou; Raymond F Schinazi
Journal:  Antivir Chem Chemother       Date:  2009-10-19

2.  Synthesis of new 2'-deoxy-2'-fluoro-4'-azido nucleoside analogues as potent anti-HIV agents.

Authors:  Qiang Wang; Weidong Hu; Shuyang Wang; Zhenliang Pan; Le Tao; Xiaohe Guo; Keduo Qian; Chin-Ho Chen; Kuo-Hsiung Lee; Junbiao Chang
Journal:  Eur J Med Chem       Date:  2011-06-23       Impact factor: 6.514

3.  4'-Azidocytidine (R1479) inhibits henipaviruses and other paramyxoviruses with high potency.

Authors:  Anne L Hotard; Biao He; Stuart T Nichol; Christina F Spiropoulou; Michael K Lo
Journal:  Antiviral Res       Date:  2017-06-17       Impact factor: 5.970

4.  Antiviral screening identifies adenosine analogs targeting the endogenous dsRNA Leishmania RNA virus 1 (LRV1) pathogenicity factor.

Authors:  F Matthew Kuhlmann; John I Robinson; Gregory R Bluemling; Catherine Ronet; Nicolas Fasel; Stephen M Beverley
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-17       Impact factor: 11.205

5.  Synthesis and anti-HIV activity of 2'-deoxy-2'-fluoro-4'-C-ethynyl nucleoside analogs.

Authors:  Qiang Wang; Yanfeng Li; Chuanjun Song; Keduo Qian; Chin-Ho Chen; Kuo-Hsiung Lee; Junbiao Chang
Journal:  Bioorg Med Chem Lett       Date:  2010-05-25       Impact factor: 2.823

6.  Iodine monochloride facilitated deglycosylation, anomerization, and isomerization of 3-substituted thymidine analogues.

Authors:  Ahmed Khalil; Keisuke Ishita; Tehane Ali; Rohit Tiwari; Ramy Riachy; Antonio Toppino; Sherifa Hasabelnaby; Naum Sayfullin; Allen G Oliver; Judith Gallucci; Zhenguo Huang; Werner Tjarks
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2014       Impact factor: 1.381

Review 7.  Antimicrobial strategies: inhibition of viral polymerases by 3'-hydroxyl nucleosides.

Authors:  Jerome Deval
Journal:  Drugs       Date:  2009       Impact factor: 9.546

8.  Efficiency of incorporation and chain termination determines the inhibition potency of 2'-modified nucleotide analogs against hepatitis C virus polymerase.

Authors:  Amy Fung; Zhinan Jin; Natalia Dyatkina; Guangyi Wang; Leo Beigelman; Jerome Deval
Journal:  Antimicrob Agents Chemother       Date:  2014-04-14       Impact factor: 5.191

Review 9.  Chutes and ladders in hepatitis C nucleoside drug development.

Authors:  Steven J Coats; Ethel C Garnier-Amblard; Franck Amblard; Maryam Ehteshami; Sheida Amiralaei; Hongwang Zhang; Longhu Zhou; Sebastien R L Boucle; Xiao Lu; Lavanya Bondada; Jadd R Shelton; Hao Li; Peng Liu; Chengwei Li; Jong Hyun Cho; Satish N Chavre; Shaoman Zhou; Judy Mathew; Raymond F Schinazi
Journal:  Antiviral Res       Date:  2013-11-23       Impact factor: 5.970

10.  Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.

Authors:  Lotte Coelmont; Suzanne Kaptein; Jan Paeshuyse; Inge Vliegen; Jean-Maurice Dumont; Grégoire Vuagniaux; Johan Neyts
Journal:  Antimicrob Agents Chemother       Date:  2008-12-22       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.